Role of Aryl hydrocarbon receptor in immunomodulation and its connection with programmed death 1

doi:10.3877/cma.j.issn.1674-0793.2021.03.014

Abstract

Abstract:

Aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor, and different ligands mediate different or even opposite effects. It has been found that AhR ligands are diverse in types and sources, which can play an important role in cell cycle, growth and development of the body, and differentiation of immune cells. Among them, the regulatory role in tumor immunity is particularly prominent. In recent years, programmed death 1 (PD-1) is an important immunosuppressive molecule, and the PD-1/ligand 1 (PD-L1) signaling pathway plays different roles in tumor immune escape, organ transplant rejection, and the occurrence and development of autoimmune diseases. AhR regulates the differentiation of lymphocytes in different directions by binding to ligands, and affects the expression of PD-1/PD-L1, thereby regulating the immune system. This article reviews the immunological effects of AhR under physiological and pathological conditions such as autoimmune diseases, tumors, transplantation, and analyze the possible relationship between AhR and PD-1.

Key words: Aryl hydrocarbon receptor, Programmed death 1, Immunomodulation, Kynurenine, Tumor immunity, PD-1/PD-L1, Transplantation immunity

Wanyue Cao, Lei Li, Tao Wang, Junming Xu. Role of Aryl hydrocarbon receptor in immunomodulation and its connection with programmed death 1[J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(03): 220-223.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2021.03.014

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2021/V15/I03/220

References 37

[1]	Neavin DR, Liu D, Ray B, et al. The role of the Aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases[J]. Int J Mol Sci, 2018, 19(12): 3851.
[2]	Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 17: 661-674.
[3]	Liu Y, Liang X, Dong W, et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation[J]. Cancer Cell, 2018, 33(3): 480-494.
[4]	Xue P, Fu J, Zhou Y. The Aryl hydrocarbon receptor and tumor immunity[J]. Front Immunol, 2018, 9: 286.
[5]	Yeung AW, Terentis AC, King NJ, et al. Role of indoleamine 2,3-dioxygenase in health and disease[J]. Clin Sci (Lond), 2015, 129(7): 601-672.
[6]	Mejía-García A, González-Barbosa E, Martínez-Guzmán C, et al. Activation of AHR mediates the ubiquitination and proteasome degradation of c-Fos through the induction of Ubcm4 gene expression[J]. Toxicology, 2015, 337: 47-57.
[7]	Ghosh J, Chowdhury AR, Srinivasan S, et al. Cigarette smoke toxins-induced mitochondrial dysfunction and pancreatitis involves Aryl hydrocarbon receptor mediated Cyp1 gene expression: protective effects of resveratrol[J]. Toxicol Sci, 2018, 166(2): 428-440.
[8]	Moreno-Marín N, Merino JM, Alvarez-Barrientos A, et al. Aryl hydrocarbon receptor promotes liver polyploidization and inhibits PI3K, ERK, and Wnt/β-Catenin signaling[J]. iScience, 2018, 4: 44-63.
[9]	Hýžd'alová M, Pivnicka J, Zapletal O, et al. Aryl hydrocarbon receptor-dependent metabolism plays a significant role in estrogen-like effects of polycyclic aromatic hydrocarbons on cell proliferation[J]. Toxicol Sci, 2018, 165(2): 447-461.
[10]	Yang SY, Ahmed S, Satheesh SV, et al. Genome-wide mapping and analysis of Aryl hydrocarbon receptor (AHR)- and Aryl hydrocarbon receptor repressor (AHRR)-binding sites in human breast cancer cells[J]. Arch Toxicol, 2018, 92(1): 225-240.
[11]	Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8:561.
[12]	Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125(9): 3384-3391.
[13]	Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111-122.
[14]	Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition[J]. Science, 2017, 355(6332): 1428-1433.
[15]	Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression[J]. Front Immunol, 2018, 9: 2374.
[16]	Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment[J]. J Immunother Cancer, 2014, 2: 3.
[17]	Kolluri SK, Jin UH, Safe S. Erratum to: role of the Aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target[J]. Arch Toxicol, 2017, 91(9): 3209.
[18]	Garcia-Villatoro EL, DeLuca J, Callaway ES, et al. Effects of high-fat diet and intestinal Aryl hydrocarbon receptor deletion on colon carcinogenesis[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G451-451, G463.
[19]	Zhu XY, Xia HG, Wang ZH, et al. In vitro and in vivo approaches for identifying the role of Aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease[J]. Toxicol Lett, 2020, 319: 85-94.
[20]	Ngui I, Perera AP, Eri R. Does NLRP3 inflammasome and Aryl hydrocarbon receptor play an interlinked role in bowel inflammation and colitis-associated colorectal cancer?[J]. Molecules, 2020, 25(10): 2427.
[21]	Baker JR, Sakoff JA, McCluskey A. The Aryl hydrocarbon receptor (AhR) as a breast cancer drug target[J]. Med Res Rev, 2020, 40(3): 972-1001.
[22]	Jin UH, Kim SB, Safe S. Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic Aryl hydrocarbon receptor pathway[J]. Chem Res Toxicol, 2015, 28(5): 907-918.
[23]	Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(1): 93-97.
[24]	Wei ZF, Lv Q, Xia Y, et al. Norisoboldine, an anti-arthritis alkaloid isolated from radix linderae, attenuates osteoclast differentiation and inflammatory bone erosion in an Aryl hydrocarbon receptor-dependent manner[J]. Int J Biol Sci, 2015, 11(9): 1113-1126.
[25]	Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the Aryl hydrocarbon receptor[J]. Nature, 2008, 453(7191): 65-71.
[26]	Goudot C, Coillard A, Villani AC, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages[J]. Immunity, 2017, 47(3): 582-596. e6.
[27]	Smits J, Ederveen T, Rikken G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides[J]. J Invest Dermatol, 2020, 140(2): 415-424. e10.
[28]	Kanai T, Naganuma M. Reply[J]. Gastroenterology, 2018, 155(2): 578-579.
[29]	Wang LT, Chiou SS, Chai CY, et al. Intestine-specific homeobox gene ISX integrates IL6 signaling, tryptophan catabolism, and immune suppression[J]. Cancer Res, 2017, 77(15): 4065-4077.
[30]	Wang GZ, Zhang L, Zhao XC, et al. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy[J]. Nat Commun, 2019, 10(1): 1125.
[31]	Xie FT, Cao JS, Zhao J, et al. IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T cells[J]. Transpl Immunol, 2015, 33(2): 69-77.
[32]	Li C, Liu T, Zhao N, et al. Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft[J]. Int Immunopharmacol, 2016, 36: 31-38.
[33]	Sun X, Gong ZJ, Wang ZW, et al. IDO-competent-DCs induced by IFN-γ attenuate acute rejection in rat liver transplantation[J]. J Clin Immunol, 2012, 32(4): 837-847.
[34]	Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality[J]. Blood, 2013, 122(17): 3062-3073.
[35]	Hossain MS, Kunter GM, El-Najjar VF, et al. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients[J]. PLoS One, 2017, 12(9): e0184254.
[36]	Curran CS, Gupta S, Sanz I, et al. PD-1 immunobiology in systemic lupus erythematosus[J]. J Autoimmun, 2019, 97: 1-9.
[37]	Inoue H, Mishima K, Yamamoto-Yoshida S, et al. Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjgren’s syndrome[J]. J Immunol, 2012, 188(9): 4654-4662.

Please choose a citation manager

Content to export